Background Differences in plasma protein levels observed between children and adults can alter the extent of xenobiotic binding in plasma, resulting in divergent patterns of exposure. Objective This study aims to quantify the ontogeny of a1-acid glycoprotein in both healthy and infected subjects. Methods Data pertaining to a1-acid glycoprotein from healthy subjects were compiled over 26 different publications. For subjects diagnosed or suspected of infection, a1-acid glycoprotein levels were obtained from 214 individuals acquired over three clinical investigations. The analysis evaluated the use of linear, power, exponential, loglinear, and sigmoid E max models to describe the ontogeny of a1-acid glycoprotein. Utility of the derived ontogeny equation for estimation of pediatric fraction unbound was evaluated using average-fold error and absolute averagefold error as measures of bias and precision, respectively. A comparison to fraction unbound estimates derived using a previously proposed linear equation was also instituted. Results The sigmoid E max model provided the comparatively best depiction of a1-acid glycoprotein ontogeny in both healthy and infected subjects. Despite median a1-acid glycoprotein levels in infected subjects being more than two-fold greater than those observed in healthy subjects, a similar ontogeny pattern was observed when levels were normalized toward adult levels. For estimation of pediatric fraction unbound, the a1-acid glycoprotein ontogeny equation derived from this work (average fold error 0.99; absolute average fold error 1.24) provided a superior predictive performance in comparison to the previous equation (average fold error 0.74; absolute average fold error 1.45). Conclusion The current investigation depicts a proficient modality for estimation of protein binding in pediatrics and will, therefore, aid in reducing uncertainty associated with pediatric pharmacokinetic predictions.
Abstract
Background Differences in plasma protein levels observed between children and adults can alter the extent of xenobiotic binding in plasma, resulting in divergent patterns of exposure. Objective This study aims to quantify the ontogeny of a1-acid glycoprotein in both healthy and infected subjects. Methods Data pertaining to a1-acid glycoprotein from healthy subjects were compiled over 26 different publications. For subjects diagnosed or suspected of infection, a1-acid glycoprotein levels were obtained from 214 individuals acquired over three clinical investigations. The analysis evaluated the use of linear, power, exponential, loglinear, and sigmoid E max models to describe the ontogeny of a1-acid glycoprotein. Utility of the derived ontogeny equation for estimation of pediatric fraction unbound was evaluated using average-fold error and absolute averagefold error as measures of bias and precision, respectively. A comparison to fraction unbound estimates derived using a previously proposed linear equation was also instituted.
Results
The sigmoid E max model provided the comparatively best depiction of a1-acid glycoprotein ontogeny in both healthy and infected subjects. Despite median a1-acid glycoprotein levels in infected subjects being more than two-fold greater than those observed in healthy subjects, a similar ontogeny pattern was observed when levels were normalized toward adult levels. For estimation of pediatric fraction unbound, the a1-acid glycoprotein ontogeny equation derived from this work (average fold error 0.99; absolute average fold error 1.24) provided a superior predictive performance in comparison to the previous equation (average fold error 0.74; absolute average fold error 1.45). Conclusion The current investigation depicts a proficient modality for estimation of protein binding in pediatrics and will, therefore, aid in reducing uncertainty associated with pediatric pharmacokinetic predictions.
Key Points
We present a mathematical description of how plasma levels of a1-acid glycoprotein, a major plasma protein responsible for binding a wide range of drugs, change between children and adults.
Developmental differences in plasma protein levels affect the magnitude of free drug available in plasma, often leading to changes in drug pharmacokinetics.
In addition to describing the developmental profile of a1-acid glycoprotein in healthy and infected subjects, the study demonstrates the utility of these profiles for estimating pediatric fraction unbound in plasma, a key parameter for fostering pharmacokinetic predictions in children.
Introduction
Plasma protein binding is a key physiological process capable of imparting influence on both pharmacokinetic (PK) and pharmacodynamic properties of xenobiotics. As such, measures of plasma protein binding are typically considered an intrinsic component for scaling PK data from preclinical species or in vitro systems towards humans [1] . Between children and adults, developmental differences in plasma protein concentrations have been documented [2] . As the extent of xenobiotic-protein binding exhibits a direct relationship to the level of plasma proteins, differences in protein binding between children and adults are expected [3] . Correspondingly, quantitative descriptions of the ontogeny of plasma proteins represent a central component of scaling pharmacokinetics between different maturational stages (i.e., intra-species scaling) [4] .
Human serum albumin and a1-acid glycoprotein (AAG) are the two major proteins present in serum with binding capacities towards a wide variety xenobiotics [5] . Whereas human serum albumin is typically associated with binding acidic exogenous compounds, AAG displays a high affinity towards basic lipophilic compounds [6, 7] . AAG is comprised of a highly glycosylated single polypeptide chain [5] with a molecular weight ranging between 41 and 43 kDa [8] . Binding of xenobiotics is facilitated by the presence of a single ligand-binding site per AAG molecule [6, 9] . In humans, the majority of AAG is present as either two or three genetic variants [10] . Furthermore, differences in ligand-binding properties between specific variants have been documented in the literature [11, 12] . For several therapeutic compounds including imipramine, propranolol, lidocaine, methadone, and chlorpromazine, AAG represents the major constituent modulating plasma binding [3] . In healthy subjects, plasma levels of AAG range from &50 to 130 mg/dL [5] . However, as an acute-phase reactant, AAG levels can increase three to five fold in response to pathologies such as Crohn's disease, myocardial infarction, infection, burns, and malignancy [7, 13] . In comparison, decreased AAG levels are associated with pregnancy, oral contraceptive use, and infancy [13] .
A highly cited evaluation of changes in plasma AAG levels associated with normal growth and development was published by McNamara and Alcorn in 2002 [2] . Using data compiled from three separate publications, the authors derived a quantitative equation (i.e., linear model) describing the relationship between postnatal age (PNA) and plasma AAG levels from birth to adulthood. Despite providing suitable estimates for older subjects, the use of a linear model appeared to overestimate AAG levels amongst the most developmentally immature subjects (i.e., newborns) [2] . In addition, an alternative ontogeny equation was proposed by Johnson et al. [14] , who used a sigmoid E max function to describe the relationship between age and plasma AAG levels. However, both the aforementioned works exclusively focused on normal/healthy subjects; whereas, utilization of therapeutic compounds is typically focused towards subjects with disease. As AAG is an acute-phase reactant, it is unclear whether these ontogeny equations can provide a suitable modality for estimating differences in AAG levels between pediatric and adult subjects with disease.
This work aims to quantitatively describe the ontogeny of serum AAG in normal (healthy) individuals as well as an additional cohort of subjects diagnosed or suspected of bacterial infection (infected). Pediatric fraction unbound in plasma (fu) data for compounds exhibiting preferential binding to AAG are used to compare the predictive capacity of the ontogeny equation derived from this work to McNamara and Alcorn's [2] seminal equation.
Methods
The present analysis evaluating the ontogeny of AAG in humans (from birth to adulthood) was divided into three corresponding subsections: (1) evaluation of AAG ontogeny in normal subjects, (2) evaluation of AAG ontogeny in subjects with known or suspected infections, and (3) comparison of the predictive performance of our prospectively derived ontogeny equation to previously proposed models [2] .
Ontogeny of a1-Acid Glycoprotein in Healthy (Normal) Subjects
To assess the relationship between age and plasma AAG levels in healthy (normal) subjects, the analysis used primary literature sources attained from the PubMed database (last accessed August 2016). Data pertaining to subjects with disease states known to alter plasma AAG levels (i.e., Crohn's disease, myocardial infarction, infection, burns, and malignancy) were excluded from the analysis. Investigations quantitatively denoting the age of participants in addition to plasma/serum AAG levels expressed in terms of central tendency (i.e., mean or median) and spread [i.e., standard deviation (SD), standard error of the mean, or percentiles] were included. Investigations reporting AAG levels among different subject groups were permitted to contribute multiple data points to the analysis. Publications that expressed data graphically were converted to numerical values using GetData Graph Digitizer v2.26 (getdatagraph-digitizer.com).
To introduce a degree of consistency between studies conducted over various publication dates, protein levels were normalized toward certified reference material (CRM) 470 values, a widely circulated serum protein calibrant developed in 1993 [15] , using the following process. For investigations conducted between 1973 and 1993 or those using protein standards manufactured during these aforementioned years, protein standards were assumed to conform to US National Reference Preparation for Serum Proteins lot 12-0575C values. AAG levels were subsequently normalized towards CRM470 values using a proportional transfer value [16] . For investigations conducted after 1993, protein standards were assumed to conform to CRM470 values. As such, no adjustment was made. Studies conducted prior to 1973 were excluded from the analysis owing to the assumed diversity in protein standards available prior to this year [17] . Quantitative assays used between studies varied and included radial immunodiffusion, nephelometry, turbidimetry, high-performance liquid chromatography, and immunoelectrophoresis. Owing to the inherent difficulty of assessing quantitative equivalence between specific assays conducted in different laboratories over various periods of time, an overarching assumption that AAG levels were equivalent between assay types was used.
In human plasma, AAG levels are log-normally distributed [18] . Considering this distributional assumption, the analysis, which complied data obtained from various investigations, required AAG levels to be expressed using log-normal parameters such as the geometric mean and log-normal standard error (log-normal SD/ ffiffi ffi n p ). For the majority of investigations, AAG levels were reported using an arithmetic mean and SD. For these studies, estimates of the geometric mean (l geo ) and log-normal standard error (SE LN ) were determined using the following equations [19] :
where m is the arithmetic mean, SD is the arithmetic SD, and n is the number of individuals examined. Two investigations [20, 21] expressed AAG levels in terms of percentiles (5th, 50th, and 95th; or 2.5th, 50th, and 97.5th). For these studies, the median (i.e., 50th percentile) was assumed to be equivalent to the geometric mean [22] . Using the assumption that log-transformation of plasma AAG levels results in a normal distribution, the SE LN was estimated using the following equation:
where Upper refers to the 95th or 97.5th AAG percentile, Lower refers to the 2.5th or 5th AAG percentile, and T #;nÀ1 is the one-sided critical t value (probability 0.95 or 0.975) associated with n -1 degrees of freedom. One investigation [23] graphically expressed neonatal AAG levels using arithmetic means and standard errors of the mean without denoting the number of subjects assessed at each time point. For this study, the geometric mean was estimated using Eq. (1) with an approximate SD value derived from additional figures from the same manuscript depicting the upper limit of normal AAG values (mean ? 2 SDs). Based on the approximation that the coefficient of variation (CV = SD/m) of a log-normally distributed variable is equal to the log-normal SD [24] , an estimate of the log-normal standard error was derived using the right-hand component of Eq. (4):
To quantitatively describe the functional relationship between age and plasma AAG levels, a variety of models were assessed: linear, power, exponential, linear-log, and sigmoid E max . Gestational ages (GA) for neonatal (preterm and term) and infant subjects' were not a universally reported among all investigations. As such, PNA was used as the primary age descriptor within this analysis. The functional form of each model is denoted in Table 1 . Parameter estimation was conducted using a maximum likelihood estimation technique with minimization of the objective function value (the negative two log-likelihood) achieved via the fminunc algorithm in Matlab R2015a (The Mathworks Inc., Natick, MA, USA). 
The covariate AGE was specified using either postnatal age (days) or postmenstrual age (weeks) b a and b denote estimable parameters associated with the linear, power, exponential, and linear-log models c AAG max [maximum plasma AAG level (mg/dL)], TM 50 [age at 50% AAG max (days or weeks)], and P (Hill coefficient) denote estimable parameters associated with the sigmoid E max model Model fits were weighted using the squared reciprocal of log-normal standard errors associated with each study group 1=SE 2 LN À Á . To impart a log-normal error structure, parameter estimation was performed using log-transformed values for observed (i.e., study-specific l geo ) and predicted AAG levels with PNA, in days, serving as the sole covariate for all fitted models (Table 1) . Because predicted plasma AAG levels at birth (i.e., PNA = 0 days) under the power and sigmoid E max model return a value of 0, the fitting algorithm, which log-transforms predictions, fails to compute (i.e., Ln(0) = undefined). In addition, the linearlog model is undefined at birth. To circumvent these operational issues, the PNA for subject groups assessed at birth (PNA = 0) were adjusted to a PNA of 1 day. This modification was deemed defensible as the l geo of AAG levels observed among subjects assessed at birth and those observed during the first day of life were similar within our dataset (19.92 vs. 17 .67 mg/dL, respectively). Model selection was performed using a combination of the Akaike Information Criterion (AIC) and a visual inspection of observed study data overlaid with predicted AAG levels to assess curve shape.
Ontogeny of a1-Acid Glycoprotein in Subjects with Diagnosed or Suspected of Infection
To evaluate the relationship between age and plasma AAG levels in patients diagnosed or suspected of infection, individual subject data were compiled over three clinical trials: [27] . The dataset consisted of a subset of subjects being treated with the antibiotic clindamycin in whom plasma AAG levels were ascertained. Age was denoted as PNA; however, GA was also recorded for subjects less than 3 months old. Inclusion/ exclusion criteria specific to each investigation is described in Table 2 .
A similar assessment as described in the previous section was instituted to select the most suitable quantitative equation (Table 1 ) to describe the relationship between plasma AAG levels and PNA. Parameter estimates were obtained via maximum likelihood estimation using a lognormal error model with minimization of the objective function value achieved using the previously described computational approach. Confidence intervals associated with estimated AAG levels were tabulated using the delta method (asymptotic theory) [24] .
An evaluation of the use of an alternative age descriptor, post-menstrual age (PMA = PNA ? GA), was also conducted using this dataset. Parameter estimates were obtained in a similar manner as depicted above but using PMA, in weeks, instead of PNA. For subjects greater than 3 months of age, PMA was calculated assuming a GA of 40 weeks. The AIC and SD of log-normalized residuals (&RMSE) between models using PMA and PNA were used to assess the goodness of fit associated with each age descriptor.
Prediction of Pediatric Fraction Unbound:
A Comparison of the a1-Acid Glycoprotein Ontogeny Equation Derived from this Study to Previously Proposed Models [2] Estimates of pediatric fu (fu ped ) were tabulated from observed adult fu (fu adult ) values and the ratio of pediatricto-adult plasma protein levels (
) using the following equation proposed by McNamara and Alcorn [2] :
To obtain P ped P adult ratios as required by Eq. (5), the derived AAG ontogeny equations, which were formulated in terms of absolute plasma levels (mg/dL), were simply divided by estimated adult AAG values. The above process also denotes how AAG estimates derived from Johnson et al.'s [14] ontogeny equation were converted to estimates of fu ped .
A set of experimentally determined fu ped values also complied by McNamara and Alcorn [2] were used to assess the predictive accuracy of estimates. The dataset consisted of 17 pairs of age-specific fu values (pediatric and adult) for 11 xenobiotics exhibiting specific affinity towards AAG. Observed fu values were predominantly determined in plasma samples from healthy or control subjects. Correspondingly, estimates of fu ped were derived using observed fu adult values from the dataset and P ped P adult ratios pertaining to the ontogeny of AAG in healthy subjects. Overall predictive performance was evaluated using the average-fold error (AFE) and absolute average-fold error (AAFE) as measures of bias and precision, respectively. The equations for both measures are given below:
where obs is the observed fu ped value from the dataset and pred is the predicted fu value based on Eq. (5 
Results
The ontogeny of plasma AAG in healthy (control) subjects was evaluated using data from 26 separate studies complied from the literature [13, 18, 20, 21, 23, . The analysis included AAG levels from subject groups that ranged in average (postnatal) age from 0 days (i.e., newborns) to 79 years. In comparison to other models fit using PNA, the sigmoid E max model was associated with the lowest AIC value (52.84) and depicted a curve shape that was visually congruent with observed AAG levels ( Fig. 1) . AIC values associated with competing models were as follows: 184.43 (linear), 95.72 (power), 189.17 (exponential), and 70.70 (linear-log). Table 3 denotes parameter estimates and associated standard errors for the sigmoid E max model. The AAG max (93.17 mg/dL) depicts the geometric mean (or median) of plasma AAG levels in healthy adults. Comparatively, the model estimates median AAG levels to be approximately 3.8-fold lower (i.e., 24.67 mg/dL) during the first day of life (day = 1). Two-hundred and fourteen individual AAG levels compiled over three separate clinical trials were used to evaluate the ontogeny of AAG in subjects diagnosed or suspected of infection. The dataset included 20 subjects from the CLIN01 trial, 177 from the PTN POPS trial, and 17 from the Staph Trio trial. Individuals ranged in PNA Table 2 Key inclusion/exclusion criteria for the three of studies that reported a1-acid glycoprotein levels among purportedly infected subjects (note: the below criteria denote those that were considered for inclusion in our analysis and not necessarily for enrollment purposes for the respective studies) from 5 days to 20.5 years. As in healthy subjects, the sigmoid E max model provided the best fit between PNA and AAG levels as determined by the AIC (319.24) and visual examination of curve shape (Fig. 2a) . In comparison, AIC values associated with the linear, power, exponential, and linear-log models were 359.87, 334.61, 360.34, and 329.76, respectively. Parameter estimates and standard errors associated with the sigmoid E max model using the covariate PNA are denoted in Table 4 . For adults diagnosed or suspected of infection, the estimated geometric mean AAG level (AAG max ; 254.71 mg/dL) was comparatively higher than values observed in healthy (normal) adults. This trend towards increased AAG levels was depicted throughout the entire developmental age range. For example, at 5 days old, median AAG levels were estimated to be 89.41 mg/dL in infected individuals compared with 41.51 mg/dL in healthy subjects. On average, AAG levels from the StaphTrio trial, which contributed data pertaining to prematurely born (\30 weeks GA) neonates and infants less than 3 months PNA, appeared to be overestimated by the sigmoid E max model fit using PNA (open square in Fig. 2a) . A similar pattern was also seen for children from the CLIN01 trial, all of whom were either overweight or obese [C85th percentile of weight for age and sex] (open triangle in Fig. 2a) . Figure 2b depicts the ontogeny of AAG derived using a sigmoid E max model employing PMA as its primary covariate for subjects diagnosed or suspected of infection. The model was associated with an AIC value of 291.02, which was comparatively lower than the previous model fit using PNA. In addition, use of PMA was associated with a lower SD of log-normalized residuals (&RMSE) in comparison to PNA (0.4710 vs. 0.5031, respectively). Correspondingly, PMA was deemed as the preferable age descriptor for defining the ontogeny of AAG within this subset of subjects. Parameter estimates and standard errors for the sigmoid E max model fit to PMA are denoted in Table 4 . The estimated AAG max (254.37 mg/dL) was similar in value to that of the PNA model; however, estimates of the age at 50% AAG max (TM 50 ) and the hill coefficient (P) were expectedly different between models, owing to the use of varying age descriptors. Additionally, use of PMA decreased the degree of over-prediction associated with AAG estimates for premature born children from the Staph-Trio trial (open square in Fig. 2b) . Though, similar to the PNA model, AAG estimates for subjects from the CLIN01 trial tended to be overestimated using PMA (open triangle in Fig. 2b) . Fig. 1 Ontogeny of a1-acid glycoprotein (AAG) among healthy subjects. Levels, normalized to CRM470 values, are depicted using estimated geometric mean values (o) for each study group. Geometric error bars depict the log-normal standard error associated with each study cohort. Predicted AAG levels based on a sigmoid E max model (red solid line), as derived from this work, and a linear model (blue dashed line), as proposed by McNamara and Alcorn (assuming adult plasma AAG levels &93.17 mg/dL) [2] , are denoted. Observed data were compiled from the following publications: [13, 18, 20, 21, 23, A graphical comparison of model-predicted AAG levels between healthy subjects and those diagnosed or suspected of infection is displayed in Fig. 3a . The comparison employed models parameterized in terms of PNA as the analysis in healthy subjects did not assess ontogeny with regard to PMA. The span of postnatal ages depicted were limited to the age range of purportedly infected subjects (i.e., 5 days-20.5 years). Normalizing AAG towards the adult levels provides an estimate of the fractional attainment of adult concentrations (i.e., P ped P adult ). Average estimates of P ped P adult ratios in healthy subjects fell within the 95% CI of values associated with subjects diagnosed or suspected of infection for the assessed age range. As a result, it was asserted that the developmental trajectory of the P ped P adult ratio was not substantially different between healthy and infected subjects (Fig. 3b) .
Overall bias associated with the use of the derived AAG ontogeny model among healthy subjects, parameterized using PNA, at estimating 17 separate fu ped values was very low. On average, estimates under-predicted observed values by 1% (AFE = 0.99). The model was associated with a precision (AAFE) of 1.24, indicating that, on average, individual predictions were within 24% of observed values. Johnson et al.'s [14] ontogeny equation performed quite similarly in terms of bias (AFE = 0.95) and precision (AAFE = 1.24). In contrast, the use of McNamara and Fig. 4 . The sigmoid E max model provided predictions that were in closer agreement to observed values as illustrated by their proximity to the line of identity. This newly developed model was associated with a higher concordance correlation coefficient in comparison to the linear model (0.851 vs. 0.652, respectively).
Discussion
For estimation of AAG levels among subjects diagnosed or suspected of infection, the analysis supported use of PMA as a comparatively better age descriptor than PNA. With use of PMA, estimated AAG levels were notably less biased for the subset of premature children from the StaphTrio trial (Fig. 2) . Use of PMA as an alternative age descriptor for assessment of the ontogeny of AAG among healthy individuals was precluded, as not all studies with neonatal subjects reported GA, thus preventing tabulation of PMA [29, 41] . Several investigations, however, have documented lower AAG levels among premature newborns in comparison to purportedly normal term newborns [23, 39, 43] . As use of PMA provides some capacity to account for prematurity, it is postulated that models using this age descriptor among healthy subjects will exhibit a better fit to AAG levels in comparison to PNA. Therefore, it is prudent that prospective studies exploring the trajectory of AAG in healthy individuals document GA among their youngest subjects to permit for PMA calculation.
As an acute-phase reactant, AAG levels increase in response to injury, inflammation, or infection [8] . The magnitude of increase has been related to factors such as the severity of disease [44] and type of infection (i.e., meningitis vs. pneumonia) [50] . Furthermore, normalization of AAG levels appear to follow the clinical course of infection [23] . Data used to evaluate the ontogeny of AAG in subjects diagnosed or suspected of infection did not provide sufficient information to stratify individuals based on infection type, severity, or time course of infection. As such, assessed subjects displayed a high degree of intersubject variability in terms of AAG levels; thus, making prediction of individual AAG levels precarious. However, Fig. 3 a Comparison of median (geometric mean) a1-acid glycoprotein (AAG) levels with respect to postnatal age in healthy (blue dotted line) and infected subjects (median, red solid line; 95% confidence interval, red dashed lines), as estimated by separate sigmoid E max models. b Comparison of normalized estimates of AAG levels (i.e., normalized to adult AAG values) with respect to postnatal age in healthy (blue dotted line) and infected subjects (median, red solid line; 95% confidence interval, red dashed lines). a1-Acid glycoprotein estimates are depicted for postnatal ages ranging between 5 days and 20.5 years for the purposes of scaling PK parameters from adult to pediatric individuals, the relative difference in AAG levels between these two age groups is the measure of interest [4, 51] . The current work demonstrates that, on average, the relative ontogeny profile of P ped P adult in infected subjects followed a similar trajectory to that observed among healthy subjects (Fig. 3b) . Correspondingly, it could be asserted that scaling of fu, as determined according to Eq. (5), from healthy or infected adults toward pediatric subjects within the same respective clinical state (e.g., infected adult to infected child) could be determined using a single ontogeny profile for P ped P adult (e.g., use of the profile pertaining to healthy subjects).
Median AAG estimates among purportedly infected, overweight and obese children from the CLIN01 trial (n = 20) were slightly over-predicted by sigmoid E max models incorporating PNA or PMA. This raises the notion of AAG levels differing between overweight and normal weight children, an observation that has been documented among 'healthy' adults [52] . However, as the dataset pertaining to infected subjects did not contain information relating to potential cofounders (e.g., infection type, severity, and time course of infection), establishing an association between the attributes (i.e., obesity) of subjects from one specific trial (CLIN01) and AAG may lack external validity and, therefore, was not pursued.
Based on an observed dataset containing 17 fu ped values, estimates of fu derived using the proposed AAG ontogeny equation from healthy (control) subjects were associated with a low bias (AFE = 0.99) and relative accurate precision (AAFE = 1.24). Discontinuity between observed and predicted fu values can be related to numerous etiologies; however, an understanding of the assumptions associated with fu prediction in pediatrics can provide some insight.
Predictions of fu ped were derived using Eq. (5), as previously depicted by McNamara and Alcorn [2] . With use of this equation, several assumptions are inherently presumed: (1) plasma protein binding is linear (i.e., non-saturable ligand levels); (2) ligand-protein binding properties are the same between children and adults (i.e., number of binding sites per protein and affinity constants are constant with age); and (3) AAG is the principal protein responsible for plasma protein binding. Violation of any of these assumptions can result in a deviation between observed and predicted values. With plasma levels up to 50-fold lower than albumin and exhibiting only a single binding site [5] , AAG is frequently termed as a low-capacity protein [3] . Consequently, therapeutic concentrations that drugs are commonly dosed towards (i.e., 1-10 lM) may result in saturation of AAG [5] . This propensity for saturation is expected to be especially prominent among neonatal subjects, where levels of AAG are considerably lower than adults. One previous study exploring protein binding of lidocaine among pediatric plasma samples asserted that age-related differences in the binding capacity of AAG between neonates and older children could be responsible for the inconsistency of fu values between the groups [39] . However, this postulation requires further study to be corroborated. Differential protein binding properties between variants of AAG have been documented in the literature [11, 12] . Unfortunately, the datasets used within this analysis did not stratify AAG into specific genetic variants; therefore, developmental changes in variant levels and their influence on protein binding estimation were not assessed. Furthermore, some xenobiotics may display affinity for more than one plasma protein. For example, the opioid antagonist naloxone displays affinity for both albumin and AAG [29] . As Eq. (5) only considers changes to a single protein, estimates of fu ped for such compounds may be biased.
Compared with the ontogeny model proposed in this study, fu ped estimates derived from McNamara and Alcorn's [2] AAG ontogeny equation were associated with a higher degree of bias and lower precision. On average, McNamara and Alcorn's equation under-predicted observed fu values by 26% (AFE = 0.74). The authors used a linear equation to describe the ontogeny of AAG ( Fig. 1 ; age is displayed on a log scale). Unfortunately, this functional form does not provide an appropriate depiction of AAG levels among the most developmentally immature subjects. For example, in neonates, the equation provided estimates of AAG levels that were well above observed data points. Therefore, considering that &80% (14/17) of fu values within the observed dataset were from neonatal subjects, the finding that fu ped estimates derived using McNamara and Alcorn's equation were associated with an under-prediction bias was not unexpected.
Considering the importance of protein binding on modulating key PK parameters such as clearance and volume of distribution [53] , an inherent understanding of how plasma proteins change as a function of age is fundamentally required to derive age-specific estimates of the time course of drug exposure in children. With an everwidening acceptance of the use of physiologically-based pharmacokinetic models for scaling xenobiotic exposures from adult to pediatric individuals [4, 54] , the findings of this analysis can be readily integrated into common practice. Physiologically-based pharmacokinetic models represent a bottom-up approach that integrates components of organism physiology with xenobiotic-specific parameters to foster a priori predictions of systemic as well as tissuespecific exposures [51] . Thus, within such models there exists an intuitive link between the quality of input parameters (i.e., physiological and xenobiotic-specific parameters) and the accuracy of model-predicted exposures. Physiologically-based pharmacokinetic models typically parameterize the magnitude of xenobiotic-protein binding using fu. By providing superior estimates of fu ped , the ontogeny model derived from this work can be used in conjunction with physiologically-based pharmacokinetic modeling techniques to improve their predictive capacity among pediatrics. This could prospectively permit such models to function as the primary exploratory investigation of pediatric drug pharmacokinetics, allowing clinical investigations to function on a confirmatory basis.
The use of a sigmoid E max model for defining the ontogeny of AAG levels is not unique to this investigation. Johnson et al. [14] previously conducted an analysis of plasma AAG levels as a function of age. The authors found that a sigmoid E max model suitably described the data. Derived parameter estimates were not considerably different from parameters reported among healthy subjects from the current study. Estimates of AAG max , TM 50 , and P were 88.7 mg/dL, 8.89 days, and 0.38, respectively. As a result, it was unsurprising that Johnson et al.'s model was associated with a similar predictive capacity as the model derived from the current analysis with regard to estimating fu ped . However, in comparison to Johnson et al.'s publication, which collated AAG data from a limited set of investigations [2, 13] , our analysis offers a more comprehensive examination of the available literature with data compiled over 26 separate investigations. The present study also considered a wider variety of prospective models and provided an evaluation of the predictive performance of the derived ontogeny equation at estimating fu ped , an important parameter used for PK scaling. In addition, the assessment of AAG ontogeny among subjects diagnosed or suspected of infection represents a component unique to the current work.
This analysis represents one of the most comprehensive examinations of published literature characterizing plasma AAG levels in healthy subjects from birth to adulthood. However, despite compiling AAG data from 26 studies conducted over a wide range of countries, the majority of data was assumedly directed towards a Caucasian population. For example, only one study was conducted in a country where the population is primarily of Asian descent (i.e., Japan) [37] . The remaining investigations, conducted in France, Canada, the Netherlands, USA, Australia, Greece, Denmark, Germany, England, and Belgium, were subsequently postulated to contain a high proportion of Caucasian subjects. Within adults, inter-ethnic differences in AAG levels have been documented. In one study, AAG levels were denoted to be 20% higher in Caucasians compared with African Americans [55] . Another investigation measuring AAG levels in Chinese and Caucasian volunteers found 25% higher levels among Caucasians [56] . Considering the demographics of individuals within the examined studies, the analysis was incapable of investigating for the presence of inter-ethnic differences among healthy subjects; therefore, presented results are primarily reflective of AAG levels within a Caucasian population. Racial demographics of individuals included in the analysis of AAG ontogeny among subjects diagnosed or suspected of infection was 76% white, 16% African American, and 8% other. A secondary analysis was conducted based on the depicted sigmoid E max model using the covariate PMA (base model) to assess whether inclusion of a binary race covariate (non-white = 0; white = 1) could enhance model fit. However, inclusion of race in a proportional manner resulted in a similar AIC to the base model (291.84 vs. 291.02, respectively). As such, use of the covariate race was not considered to be beneficial for the estimation of AAG among our sample of purportedly infected subjects.
In this study, the ontogeny of AAG among healthy subjects was assessed using AAG concentration data averaged over multiple subjects from separate publications. Analyses of this type can be influenced by the presence of an aggregation bias (ecological fallacy). This bias arises from the loss of information associated with aggregating individual data, leading to distortion of the relationship that exists between individual subjects and the variable of interest [57] . Despite this, use of aggregated data within the analysis was deemed reasonable as the majority of publications failed to report individualized values. In addition, the ontogeny models derived from this investigation should not be considered to entail wider applicability towards other plasma proteins (e.g., albumin), which can follow alternative ontogeny patterns [2] .
Conclusion
The current investigation sought to quantitatively describe the ontogeny of AAG in both healthy subjects and those diagnosed or suspected of infection. A sigmoid E max model was found to best describe the developmental trajectory of AAG in both groups of subjects (healthy and infected). As an acute-phase reactant, plasma AAG levels increase in response injury, inflammation, and infection [7] . Though a profound dissimilarity in median AAG concentrations between healthy and infected subjects was observed, the analysis depicted a similar ontogeny pattern when AAG levels were normalized toward adult values. Furthermore, the derived ontogeny equation demonstrated a proficient predictive capacity for estimation of fu ped . As developmental changes in plasma protein binding (i.e., fu) can translate into significant alterations in compound distribution and clearance, this work will aid in reducing uncertainty associated with pediatric PK predictions.
